Journal
THROMBOSIS AND HAEMOSTASIS
Volume 106, Issue 4, Pages 572-584Publisher
GEORG THIEME VERLAG KG
DOI: 10.1160/TH11-04-0262
Keywords
Atrial fibrillation; antithrombotic therapy; warfarin; triple therapy; stent
Categories
Funding
- AstraZeneca
- Bristol-Myers Squibb
- Eisai
- Sanofi-aventis
- The Medicines Company
- Astra-Zeneca
- Boehringer-Ingelheim
- Bristol-Myer-Squibb
- Corgenix
- Daiichi-Sankyo
- Eli-Lilly
- Glaxo-Smith-Kline
- Haemoscope
- McNeil
- Accumetrics
- Aspirin Works
- Bayer
- Dade-Behring
- Bristol Myers Squibb/Sanofi-Aventis
- GlaxoSmithKline
- Otsuka
- Boston Scientific
- Eli Lilly Co
- Daiichi Sankyo, Inc.
- Portola
- Schering-Plough
- Johnson and Johnson
- Thrombovision
- Helena
- AstraZeneca, Haemoscope
- Corgenix/Aspirinworks
Ask authors/readers for more resources
The optimal regimen of the anticoagulant and antiplatelet therapies in patients with atrial fibrillation who have had a coronary stent is unclear. It is well recognised that triple therapy with aspirin, clopidogrel, and warfarin is associated with an increased risk of bleeding. National guidelines have not made specific recommendations given the lack of adequate data. In choosing the best antithrombotic options for a patient, consideration needs to be given to the risks of stroke, stent thrombosis and major bleeding. This document describes these risks, provides specific recommendations concerning vascular access, stent choice, concomitant use of proton-pump inhibitors and the use and duration of triple therapy following stent placement based upon the risk assessment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available